Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
159
Website
SMMT Metrics
BasicAdvanced
$20B
-
-$0.34
-0.46
-
Price and volume
Market cap
$20B
Beta
-0.46
52-week high
$36.91
52-week low
$8.80
Average daily volume
3.8M
Financial strength
Current ratio
10.63
Quick ratio
10.36
Long term debt to equity
0.844
Total debt to equity
1.873
Interest coverage (TTM)
-42.31%
Profitability
EBITDA (TTM)
-235.366
Management effectiveness
Return on assets (TTM)
-52.50%
Return on equity (TTM)
-123.93%
Valuation
Price to book
56.73
Price to tangible book (TTM)
57.05
Price to free cash flow (TTM)
-101.563
Free cash flow yield (TTM)
-0.98%
Free cash flow per share (TTM)
-25.93%
Growth
Earnings per share change (TTM)
105.02%
3-year earnings per share growth (CAGR)
-29.38%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
Bulls say / Bears say
Summit Therapeutics' experimental lung cancer drug, ivonescimab, demonstrated superior progression-free survival compared to Merck's Keytruda in a late-stage study conducted in China, leading to a significant surge in the company's stock price. (reuters.com)
The company successfully raised approximately $235 million through a private placement, with significant participation from insiders and leading biotech institutional investors, providing substantial capital to advance clinical development. (finance.yahoo.com)
Summit Therapeutics has entered advanced negotiations with AstraZeneca for the potential licensing of ivonescimab, in a deal reportedly valued up to $15 billion, indicating strong interest from major pharmaceutical companies. (simplywall.st)
Despite positive trial results, Summit's stock experienced a significant decline due to market concerns over the China-only data and the drug's current unavailability in the U.S. market. (seekingalpha.com)
The company reported a wider-than-expected net loss of $61.1 million in Q4, slightly exceeding analysts' estimates, raising concerns about its financial health. (tradingview.com)
Analyst sentiment has shifted, with Piper Sandler downgrading the stock to 'Underweight' due to increased legal and regulatory risks, reflecting growing caution among investors. (monexa.ai)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Business Wire·1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $20B as of July 23, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of July 23, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of July 23, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -0.46. This means that it has an inverse relation to market volatility.